AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
Contact information
James Rock jimrock@aribiousa.com
AriBio USA Branch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 20:04:00 EEST | Press release
Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma
Introducing Joblio – The Future of Ethical Recruitment12.5.2025 19:30:00 EEST | Press release
Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized expert in global labor migration law and international workforce mobility, Jon ha
DEWA Announces Record Quarterly Revenue of AED 5.96 Billion and Quarterly Cash from Operations of AED 3.85 Billion12.5.2025 18:06:00 EEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, listed on the Dubai Financial Market (DFM), reported its first quarter 2025 consolidated financial results, recording quarterly revenue of AED 5.96 billion, EBITDA of AED 2.43 billion, operating profit of AED 838 million and net profit of AED 496 million. The company also generated a record net cash from operations of AED 3.85 billion resulting in closing cash and cash equivalents of AED 8.17 billion, which is AED 2.07 billion higher than the balance as at year-end 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512715455/en/ Dubai Electricity and Water Authority announces record quarterly revenue of AED 5.96 billion and quarterly Cash from Operations of AED 3.85 billion (English Graphic: AETOSWire) “We are progressing in our journey to Net Zero by 2050 and will con
Alisher Usmanov Wins Legal Case Against Luxembourg’s Largest Media Group, Says Law Firm Rechtsanwälte Steinhöfel12.5.2025 15:43:00 EEST | Press release
A German court has banned Mediahuis Luxembourg S.A., the most important media holding in Luxembourg, from referring to Alisher Usmanov as the owner of the yacht Dilbar. Mediahuis Luxembourg is the leading publishing company in Luxembourg, with such assets as newspapers and online platforms, including Luxemburger Wort, Luxembourg Times and others. On May 5, 2025, the Regional Court of Hamburg ruled that the following statement published by Luxembourg Times was false and prohibited its further publication: “The luxury yacht Dilbar was seized in Hamburg’s harbour in 2022 following Russia’s invasion under EU sanctions. The yacht is owned through a company and trust by Uzbek-Russian billionaire Alisher Usmanov.” The court found the statement to be in violation of Mr. Usmanov’s rights and prohibited its distribution. In the event of non-compliance with the prohibition, Mediahuis may be fined up to €250,000 for each individual offense. Moreover, if such a fine is not enforceable, it may be re
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202512.5.2025 15:23:00 EEST | Press release
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2025. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €603.4 million, an increase of 8.9% compared to the corresponding data for 2024. All indicators are positive for the period. In the first quarter of 2025 the consolidated EBITDA was €105.3 million compared to €87.3 million in 2024, equal to 17.5% of the turnover. EBIT, from January to March, was €88.7 million (€72.1 million in 2024) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €86.9 million (€73.1 million in 2024), equal to 14.4% of the turnover. The net financial position of the Group on 31 March 2025 is also positive by 537.0 million. The net financial position on 31 December 2024 was positive for €349.1 million. “The close of 2024 and the positive start of 2025,’ said Mario Rizzante, Reply Chairman, ‘reaffirm both the solidity of the Reply model
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom